



STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2014

PART - I

Rs. in lakhs

Sl. No.	PARTICULARS	Quarter ended			Previous year ended
		30/06/2014	31/03/2014	30/06/2013	31/03/2014
		Un-audited	Audited	Un-audited	Audited
1	Income from operations				
	(a) Net sales/income from operations (Net of excise duty)	14,153.16	13,080.34	10,866.96	51,031.24
	(b) Other operating income	-	-	-	-
	Total income from operations (net) (a)+(b)	14,153.16	13,080.34	10,866.96	51,031.24
2	Expenses				
	a) Cost of materials consumed	4,695.34	3,898.42	3,374.55	15,049.65
	b) Purchases of stock-in-trade	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(47.88)	339.57	14.69	(1,397.66)
	d) Employee benefits expense	911.37	710.62	779.83	3,144.21
	e) Depreciation and amortisation expense	238.86	227.51	209.48	883.74
	f) Other expenses - Manufacturing Expenses	1,439.61	1,600.29	1,159.51	5,388.94
	- R & D Expenses	894.89	1,238.05	793.87	4,794.79
	- Others	471.67	549.70	441.32	2,145.45
	Total expenses	8,603.86	8,564.16	6,773.25	30,009.12
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	5,549.30	4,516.18	4,093.71	21,022.12
4	Other Income	107.94	120.29	315.53	302.95
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	5,657.24	4,636.47	4,409.24	21,325.07
6	Finance costs	116.42	169.51	319.06	1,051.28
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 - 6)	5,540.82	4,466.96	4,090.18	20,273.79
8	Exceptional Items	405.99	-	-	-
9	Profit/Loss from Ordinary Activities before tax (7 + 8)	5,134.83	4,466.96	4,090.18	20,273.79
10	Tax Expenses	1,661.01	1,226.40	1,112.99	5,858.04
11	Net Profit/ (Loss) from Ordinary Activities after tax (9-10)	3,473.82	3,240.56	2,977.19	14,415.75
12	Extraordinary Items (net of tax expense Rs____)	-	-	-	-
13	Net Profit / (Loss) for the period (11 + 12)	3,473.82	3,240.56	2,977.19	14,415.75
14	Share of profit / (loss) of associates	-	-	-	-
15	Minority interest	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15)	3,473.82	3,240.56	2,977.19	14,415.75
17	Paid-up equity share capital (Face Value of Rs. 1/- each)	1,168.29	1,168.29	1,168.29	1,168.29
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	25,276.34
19.i	Earnings Per Share (EPS) (before extraordinary items) (of Rs.1/- each) (not annualised):				
	a) Basic	2.97	2.77	2.55	12.34
	b) Diluted	2.97	2.77	2.55	12.34
19.ii	Earnings Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):				
	a) Basic	2.97	2.77	2.55	12.34
	b) Diluted	2.97	2.77	2.55	12.34

PART - II		30/06/2014	31/03/2014	30/06/2013	31/03/2014
A	PARTICULARS OF SHAREHOLDING	Un-audited	Audited	Un-audited	Audited
1	Public share holdings				
	a. Number of shares	41,171,212	41,171,212	41,171,212	41,171,212
	b. Percentage of share holding	35.24%	35.24%	35.24%	35.24%
2	Promoters and promoter group Shareholding				
	a) Pledged / Encumbered				
	- Number of shares	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL
	b) Non-Encumbered				
	- Number of shares	75,657,576	75,657,576	75,657,576	75,657,576
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	64.76%	64.76%	64.76%	64.76%
Particulars		3 months ended (30/06/2014)			
B	INVESTOR COMPLAINTS				
	Pending at the beginning of the quarter	1			
	Received during the quarter	76			
	Disposed of during the quarter	77			
	Remaining unresolved at the end of the quarter	-			


SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED

PARTICULARS	Quarter ended			Previous year ended
	30/06/2014	31/03/2014	30/06/2013	31/03/2014
	Un-audited	Audited	Un-audited	Audited
1 SEGMENT REVENUE				
a) Manufacturing (CRAMS)	13,894.85	12,683.57	10,688.52	49,344.00
b) Services (DDDSS)	258.21	396.78	178.43	1,687.24
c) Research & Development	-	-	-	-
Net sales/income from operations	14,153.06	13,080.35	10,866.95	51,031.24
2 SEGMENT RESULTS (Profit/(Loss) before tax and interest)				
a) Manufacturing (CRAMS)	6,731.05	5,937.20	5,179.70	26,308.56
b) Services (DDDSS)	34.89	200.73	15.83	888.72
c) Research & Development	(1,241.35)	(1,238.05)	(793.87)	(4,794.79)
TOTAL	5,524.59	4,899.88	4,401.66	22,402.49
Less: (i) Interest	77.56	89.44	217.43	618.92
(ii) Other Un-allocable expenses net off	312.20	343.47	94.04	1,509.78
(iii) un-allocable Income	-	-	-	-
Profit Before Tax	5,134.83	4,466.97	4,090.19	20,273.79
3 CAPITAL EMPLOYED (Segment Assets - Segment Liabilities)				
a) Manufacturing (CRAMS)	22,445.39	19,509.25	17,627.07	19,509.25
b) Services (DDDSS)	3,371.36	3,493.63	3,286.00	3,493.63
c) Research & Development	1,198.81	1,815.26	2,684.65	1,815.26
d) Net assets which are not segmented and used commonly	2,429.38	1,626.50	787.01	1,626.50
TOTAL	29,444.94	26,444.64	24,384.73	26,444.64

Notes:

- The above Un-audited results were approved and taken on record at the Board of Directors' Meeting held on 12th August, 2014.
- Previous year(s) figures have been regrouped/reclassified whenever necessary.
- The depreciation has been computed as per Schedule II of the Companies Act 2013 effective April 1, 2014. Accordingly the depreciation for the qtr ended 30/06/2014 is higher by **Rs. 405.99 Lakhs** shown as exceptional item. Further, based on transitional provision in note 7(b) of schedule II an amount of **Rs. 473.50 Lakhs** (net of deferred tax of **Rs. 243.81 Lakhs**) has been adjusted with the opening Reserves.
- The above results are reviewed by Statutory Auditors.

For SUVEN LIFE SCIENCES LTD



VENKAT JASTI
Chairman & CEO

Place : Hyderabad
Date: 12th August, 2014

We Deliver



Ref No.LR/003/2014-15:

LIMITED REVIEW REPORT

To

The Board of Directors of
M/s. SUVEN LIFE SCIENCES LIMITED

We have reviewed the accompanying statement of unaudited financial results of M/S. SUVEN LIFE SCIENCES LIMITED, having registered office at 8-2-334, 6th Floor, SDE Serene Chambers, Road No.7, Banjara Hills, Hyderabad – 34, for the period ended on 30.06.2014, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India*. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for KARVY & CO.,
Chartered Accountants
(Registration No.001757S)

(K. AJAY KUMAR)
P A R T N E R
M.No.021989



Place: Hyderabad
Date : 12/08/2014



News Release

Suven achieved a PAT of Rs.34.73 Crores for first Qtr of 2014-15, an increase of 16.68% compared to same quarter of previous year

HYDERABAD, INDIA (12th August, 2014) – Suven Life Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter and year ended 30th Jun 2014. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 12th Aug 2014 at Hyderabad.

Financial Highlights for the 1st Quarter ended June, 2014:

Growth in revenue	Rs 1426 Mn vs. Rs 1118 Mn	- Up by 28%
Growth in PAT	Rs 347 Mn vs. Rs 298 Mn	- Up by 17%
Growth in EBIDTA	Rs 590 Mn vs. Rs 462 Mn	- Up by 28%

PAT during the quarter was reduced by Rs. 40.6 Mn, a charge of additional depreciation computed as per Schedule II of the Companies Act 2013 effective April 1, 2014, shown as exceptional item in Profit & Loss Account. Had the similar provisions of same quarter of previous years would have been followed, the PAT for this quarter would have been higher by Rs. 40.6 Mn.

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 89 Mn (6.28% on revenue) for the Qtr ended June' 2014.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

Suven Life Sciences Limited

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor I

Road No.5 I Avenue 7 I Banjara Hills I Hyderabad – 500 034 I Telangana I India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com